MaxCyte Price To Sales Ratio from 2010 to 2024
| MXCT Stock | USD 3.52 0.14 4.14% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 11.7555212 | Current Value 11.17 | Quarterly Volatility 49.48129258 |
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.4 M, Interest Expense of 138.6 K or Selling General Administrative of 31.6 M, as well as many indicators such as Price To Sales Ratio of 11.17, Dividend Yield of 0.0 or PTB Ratio of 2.2. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
MaxCyte | Price To Sales Ratio |
Latest MaxCyte's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of MaxCyte over the last few years. Price to Sales Ratio is figured by comparing MaxCyte stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on MaxCyte sales, a figure that is much harder to manipulate than other MaxCyte multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. MaxCyte's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 8.14 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
MaxCyte Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 69.30 | |
| Geometric Mean | 50.53 | |
| Coefficient Of Variation | 71.41 | |
| Mean Deviation | 41.83 | |
| Median | 52.21 | |
| Standard Deviation | 49.48 | |
| Sample Variance | 2,448 | |
| Range | 135 | |
| R-Value | (0.96) | |
| Mean Square Error | 194.18 | |
| R-Squared | 0.93 | |
| Slope | (10.65) | |
| Total Sum of Squares | 34,278 |
MaxCyte Price To Sales Ratio History
About MaxCyte Financial Statements
MaxCyte shareholders use historical fundamental indicators, such as Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 11.76 | 11.17 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.